Economic value of extended-window intravenous alteplase in posterior circulation stroke: a Markov analysis based on the EXPECTS trial.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of intravenous alteplase compared with standard medical therapy alone for patients with posterior circulation ischemic stroke (PCIS) presenting 4.5-24 h after symptom onset, from the perspective of the Chinese healthcare system.

Methods

A hybrid decision tree and Markov model was developed to simulate disease progression over a lifetime horizon (30 years). Clinical efficacy, utility values, and cost data were derived from the EXPECTS randomized controlled trial and domestic database. The primary outcome was the incremental cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life year (QALY) gained. Cost-effectiveness was assessed against a willingness-to-pay (WTP) threshold of one time China's per capita

SUBMITTER: Ma Y 

PROVIDER: S-EPMC12823860 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature